Aytu BioPharma (NASDAQ:AYTU) Issues Quarterly Earnings Results

by · The Cerbat Gem

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%. The business had revenue of $17.98 million for the quarter.

Aytu BioPharma Price Performance

Shares of Aytu BioPharma stock traded down $0.49 on Friday, hitting $2.36. The company had a trading volume of 237,675 shares, compared to its average volume of 20,737. The stock has a 50-day moving average of $2.52 and a 200-day moving average of $2.82. Aytu BioPharma has a twelve month low of $1.87 and a twelve month high of $3.50. The firm has a market capitalization of $14.09 million, a P/E ratio of -0.90 and a beta of -1.43.

Aytu BioPharma Company Profile

(Get Free Report)

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.

Recommended Stories